Trial · NCT07886450
Oculomotor-Pupillary AI Biomarkers in Parkinson's
NCT07886450, Not yet recruiting, The Hong Kong Polytechnic University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Oculomotor-Pupillary AI Biomarkers in Parkinson's. Trials, record NCT07886450. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886450
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oculomotor-Pupillary AI Biomarkers in Parkinson's
- NCT number
- NCT07886450
- Status
- Not yet recruiting
- Enrollment
- 128 participants, estimated
- Lead sponsor
- The Hong Kong Polytechnic University
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- Edge-AI Eye-Tracking Assessment
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Differences in mean prosaccade gain between early-to-moderate PD patients and healthy controls. | Baseline | Prosaccade gain is defined as the ratio of the primary saccade amplitude to the target displacement amplitude, measured using a head-mounted infrared eye-tracking device. The mean gain across valid trials will be calculated for each participant. Mean prosaccade gain will be compared between patients with early-to-moderate PD and healthy controls. |
| Primary | Differences in antisaccade directional error rate between early-to-moderate PD patients and healthy controls. | Baseline | Antisaccade directional error rate is defined as the percentage of valid antisaccade trials in which the initial saccade is incorrectly directed toward the visual target rather than in the opposite direction, measured using a head-mounted infrared eye-tracking device. The error rate will be calculated for each participant as the number of directional error trials divided by the total number of valid antisaccade trials, multiplied by 100. Antisaccade directional error rate will be compared between patients with early-to-moderate PD and healthy controls. |
| Primary | Differences in mean prosaccade peak velocity between early-to-moderate PD patients and healthy controls. | Baseline | Prosaccade peak velocity is defined as the maximum angular eye velocity during the primary prosaccade, measured in degrees per second (°/s) using a head-mounted infrared eye-tracking device. The mean peak velocity across valid trials will be calculated for each participant. Mean prosaccade peak velocity will be compared between patients with early-to-moderate PD and healthy controls. |
| Secondary | Correlation Between Changes in Prosaccade Gain and MDS-UPDRS Part III Scores Over 12 Months | Baseline to 12 months | The correlation between changes in mean prosaccade gain and changes in motor symptom severity will be assessed in patients with PD over 12 months. Mean prosaccade gain will be measured using a head-mounted infrared eye-tracking device, while motor symptom severity will be assessed using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III). Changes in both measures will be calculated from baseline to 12 months, and their association will be quantified using a correlation coefficient (r). |
| Secondary | Correlation Between Changes in Antisaccade Directional Error Rate and MoCA Scores Over 12 Months | Baseline to 12 months | The correlation between changes in antisaccade directional error rate and changes in cognitive function will be assessed in patients with PD over 12 months. Antisaccade directional error rate is defined as the percentage of valid antisaccade trials in which the initial saccade is incorrectly directed toward the visual target, measured using a head-mounted infrared eye-tracking device. Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). Changes in both measures from baseline to 12 months will be calculated, and their association will be quantified using a correlation coefficient (r). |
| Secondary | Area Under the Receiver Operating Characteristic Curve (AUC) for PD Classification | Baseline | The diagnostic performance of an edge-AI model based on oculomotor-pupillary features measured using a head-mounted infrared eye-tracking device will be evaluated for distinguishing patients with PD from healthy controls. Model performance will be assessed using AUC, with values ranging from 0 to 1, where higher values indicate better discriminative performance. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Antisaccade Task | Primary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886450
GET https://conductscience.org/api/trials/v1/NCT07886450/registered